375 related articles for article (PubMed ID: 29856861)
41. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
42. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
43. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
44. Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors.
Sperduto PW; De B; Li J; Carpenter D; Kirkpatrick J; Milligan M; Shih HA; Kutuk T; Kotecha R; Higaki H; Otsuka M; Aoyama H; Bourgoin M; Roberge D; Dajani S; Sachdev S; Gainey J; Buatti JM; Breen W; Brown PD; Ni L; Braunstein S; Gallitto M; Wang TJC; Shanley R; Lou E; Shiao J; Gaspar LE; Tanabe S; Nakano T; An Y; Chiang V; Zeng L; Soliman H; Elhalawani H; Cagney D; Thomas E; Boggs DH; Ahluwalia MS; Mehta MP
Int J Radiat Oncol Biol Phys; 2022 Sep; 114(1):60-74. PubMed ID: 35331827
[TBL] [Abstract][Full Text] [Related]
45. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
Li W; Song P; Guo L; Liu X; Guo C; Ying J; Gao S
Thorac Cancer; 2019 Feb; 10(2):175-182. PubMed ID: 30536734
[TBL] [Abstract][Full Text] [Related]
46. Expression of PD-L1, cancer stem cell and epithelial-mesenchymal transition phenotype in non-small cell lung cancer.
Koh YW; Han JH; Haam S
Pathology; 2021 Feb; 53(2):239-246. PubMed ID: 33036771
[TBL] [Abstract][Full Text] [Related]
47. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
48. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
[TBL] [Abstract][Full Text] [Related]
49. PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations.
Mansour MSI; Malmros K; Mager U; Ericson Lindquist K; Hejny K; Holmgren B; Seidal T; Dejmek A; Dobra K; Planck M; Brunnström H
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562908
[TBL] [Abstract][Full Text] [Related]
50. Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
Yanagawa N; Shiono S; Endo M; Ogata SY; Yamada N; Sugimoto R; Osakabe M; Uesugi N; Sugai T
Hum Pathol; 2021 Feb; 108():12-21. PubMed ID: 33159965
[TBL] [Abstract][Full Text] [Related]
51. Various impacts of driver mutations on the PD-L1 expression of NSCLC.
Chu CH; Huang YH; Lee PH; Hsu KH; Chen KC; Su KY; Yu SL; Tseng JS; Yang TY; Chang GC
PLoS One; 2022; 17(8):e0273207. PubMed ID: 35980949
[TBL] [Abstract][Full Text] [Related]
52. Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
Yang CY; Lin MW; Chang YL; Wu CT
Cancer Biomark; 2017 Dec; 21(1):211-220. PubMed ID: 29036791
[TBL] [Abstract][Full Text] [Related]
53. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
54. Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.
Serra P; Petat A; Maury JM; Thivolet-Bejui F; Chalabreysse L; Barritault M; Ebran N; Milano G; Girard N; Brevet M
Lung Cancer; 2018 Apr; 118():62-68. PubMed ID: 29572005
[TBL] [Abstract][Full Text] [Related]
55. Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
Tancoš V; Farkašová A; Kviatkovská Z; Grendár M; Líšková A; Huťka Z; Plank L
Pathol Res Pract; 2020 Dec; 216(12):153238. PubMed ID: 33059241
[TBL] [Abstract][Full Text] [Related]
56. Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India.
Kulshrestha R; Saxena H; Kumar R; Spalgais S; Mrigpuri P; Goel N; Menon B; Rani M; Mahor P; Bhutani I
Monaldi Arch Chest Dis; 2023 Feb; 93(4):. PubMed ID: 36723380
[TBL] [Abstract][Full Text] [Related]
57. Comparison of
Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
[TBL] [Abstract][Full Text] [Related]
58. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
Song Z; Yu X; Cheng G; Zhang Y
J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
[TBL] [Abstract][Full Text] [Related]
59. The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer.
Kim GJ; Lee JH; Park WJ; Lee HW; Hwang IS; Lee DH
Ann Clin Lab Sci; 2019 May; 49(3):317-323. PubMed ID: 31308030
[TBL] [Abstract][Full Text] [Related]
60. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
